Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.

Revenue projections:

Revenue projections for APLLTD
Revenue projections for APLLTD

Investors may be wary of APLLTD as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 0.00000
forwardPE 17.79944
debtToEquity 28.00400
earningsGrowth -0.03600
revenueGrowth 0.10800
grossMargins 0.71510
operatingMargins 0.11372
trailingEps 32.09000
forwardEps 42.30470

With APLLTD's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
APLLTD's low Debt-to-Equity ratio highlights its minimal reliance on debt, showing that the company is not over-leveraged. This contributes to lower financial risk and greater stability, giving APLLTD a stronger position in managing its financial obligations.
Alembic Pharmaceuticals Limited's low growth in both earnings and revenue indicates the company's profits may decrease. This trend could signal a downturn in financial performance, suggesting that Alembic Pharmaceuticals Limited might struggle to maintain its current profit levels.
Alembic Pharmaceuticals Limited's negative gross and operating margins highlight that the company is incurring losses, unable to generate profit from production or operations. This could be a sign of rising costs or declining revenues, impacting its financial outlook.
APLLTD's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that APLLTD is likely to outperform its previous year's financial performance.

Price projections:

Price projections for APLLTD
Price projections for APLLTD

The price of Alembic Pharmaceuticals Limited has remained consistently close to the lower limit of projections. This ongoing pattern raises concerns about the stock's performance and may reflect market hesitance regarding the company's growth prospects.

Insider Transactions:

Insider Transactions for APLLTD
Insider Transactions for APLLTD


There were 20 buy transactions of Alembic Pharmaceuticals Limited, with market price at 881.7800018310547.The period under consideration saw no buy transactions.APLLTD's current price levels are marked by more sells than buys, potentially signaling a price decline. If this trend continues, it may suggest that investors expect the stock to drop further in value.

Recommendation changes over time:

Recommendations trend for APLLTD
Recommendations trend for APLLTD


Analysts' recent buy bias toward Alembic Pharmaceuticals Limited suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see Alembic Pharmaceuticals Limited as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.